Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9622131 | 0.90 | MEN1 (0.42) | MEN1KMT2APOLBSMN1; SMN2LMNA | |
| SCHEMBL17732684 | 0.88 | MEN1 (0.39) | MEN1KMT2APOLBSMN1; SMN2LMNA | |
| SCHEMBL10829078 | 0.88 | MEN1 (0.42) | MEN1KMT2APOLBSMN1; SMN2LMNA | |
| SCHEMBL10916857 | 0.85 | MEN1 (0.41) | MEN1KMT2APOLBSLC6A3KDM4C | |
| SCHEMBL8535080 | 0.83 | MEN1 (0.40) | MEN1KMT2APOLBSMN1; SMN2LMNA | |
| SCHEMBL16054972 | 0.83 | KMT2A (0.43) | MEN1KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL9782612 | 0.82 | KMT2A (0.39) | MEN1KMT2APOLBLMNASLC6A3 | |
| SCHEMBL10827794 | 0.82 | MEN1 (0.42) | MEN1KMT2APOLBSLC6A3ALDH1A1 | |
| SCHEMBL10828051 | 0.81 | KDM4E (0.39) | MEN1KMT2APOLBSLC6A3KDM4C | |
| SCHEMBL10827594 | 0.81 | MEN1 (0.36) | MEN1KMT2APOLBSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | JINA PHARMACEUTICALS, INC. | 2021-06-17 | — | — | US | disclosed |
| US-10376479-B2 | Endoxifen compositions and methods | JINA PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190231687-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | JINA PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| EP-2101731-B1 | ENDOXIFEN FOR USE IN THE TREATMENT OF CANCER | JINA PHARMACEUTICALS INC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20160346230-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160346230-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9333190-B2 | Endoxifen compositions and methods | JINA PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9333190-B2 | Endoxifen compositions and methods | JINA PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20120164075-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120164075-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20100112041-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100112041-A1 | Endoxifen Compositions And Methods | JINA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20090291134-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291134-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | JINA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112041-A1 | Endoxifen Compositions And Methods | CYP46A1, PLA2G2F, VDR | MEN1 1461/4885KMT2A 3054/4885POLB 4664/4885 |
| US-20160346230-A1 | Endoxifen Compositions And Methods | CYP46A1, PLA2G2F, VDR | MEN1 1461/4885KMT2A 3054/4885POLB 4664/4885 |
| US-20090291134-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | NLN, BDNF, LITAF | MEN1 3386/4885KMT2A 2431/4885POLB 2993/4885 |
| US-10376479-B2 | Endoxifen compositions and methods | CYP46A1, PLA2G2F, VDR | MEN1 1461/4885KMT2A 3054/4885POLB 4664/4885 |
| US-20120164075-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES | ENPP2, ERAL1, LITAF | MEN1 1341/4885KMT2A 3295/4885POLB 3524/4885 |
| US-20190231687-A1 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES | NLN, BDNF, LITAF | MEN1 3386/4885KMT2A 2431/4885POLB 2993/4885 |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | EEF2K, LITAF, RAPGEF3 | MEN1 4138/4885KMT2A 2646/4885POLB 3748/4885 |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | EEF2K, LITAF, RAPGEF3 | MEN1 4138/4885KMT2A 2646/4885POLB 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.